nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-CD6D3DFC·Framework v5.9·Pipeline v0.4·Evaluated 28 Sept 2026·OECD: 3.2 Public health and health services·Subfield: Public Health, Environmental and Occupational Health·Basis: Full text·Type: Narrative review

A 10-year update to the principles for clinical trial data sharing by pharmaceutical companies: perspectives based on a decade of literature and policies.

Modi et al.Modi, Kichenadasse, Hoffmann et al.·2023·BMC medicine·10.1186/s12916-023-03113-0 ↗

In brief

An actionable update to industry data-sharing principles that consolidates a decade of policy development, but lacks a transparent source-selection method.

ReliabilityNo concerns4 of 4 checks completeSee what was checked ↓
Abstract

Data sharing is essential for promoting scientific discoveries and informed decision-making in clinical practice. In 2013, PhRMA/EFPIA recognised the importance of data sharing and supported initiatives to enhance clinical trial data transparency and promote scientific advancements. However, despite these commitments, recent investigations indicate significant scope for improvements in data sharing by the pharmaceutical industry. Drawing on a decade of literature and policy developments, this article presents perspectives from a multidisciplinary team of researchers, clinicians, and consumers. The focus is on policy and process updates to the PhRMA/EFPIA 2013 data sharing commitments, aiming to enhance the sharing and accessibility of participant-level data, clinical study reports, protocols, statistical analysis plans, lay summaries, and result publications from pharmaceutical industry-sponsored trials. The proposed updates provide clear recommendations regarding which data should be shared, when it should be shared, and under what conditions. The suggested improvements aim to develop a data sharing ecosystem that supports science and patient-centred care. Good data sharing principles require resources, time, and commitment. Notwithstanding these challenges, enhancing data sharing is necessary for efficient resource utilization, increased scientific collaboration, and better decision-making for patients and healthcare professionals.

Key Claims

Key claims could not be produced for this evaluation. The rest of the evaluation is unaffected.

Strengths · Limitations

Strengths

#contribution

Operational policy framework with clear timelines

Table 1 specifies which materials should be shared, proposed timing, governance arrangements, supporting documentation, and public-policy formats. This moves beyond a general endorsement of transparency toward language that policy teams could adapt.

↳ Enhancing Data Sharing Practices, Table 1

#reporting

Traceable issue-to-recommendation structure

Each major section begins from an established policy position, describes subsequent developments, and connects them to a proposed update. The six-part structure mirrors Table 1 and keeps the argument legible.

↳ Participant-Level Data Sharing through Public Data Sharing Policies; Table 1

#application pathway

Visible pathway to policy use

The article names pharmaceutical companies, PhRMA/EFPIA, regulators, review panels, sponsors, and sharing platforms as relevant actors. Its proposed public registers, timelines, and standardised policy formats give those actors concrete points of intervention.

↳ Progress and Challenges in Clinical Trial Data Sharing; Table 1; Conclusions

Limitations

#methodological rigour

Source-selection method remains unreported

The article states that it draws on a decade of literature and reported experience but provides no search strategy, inclusion criteria, coverage dates, or appraisal process. This limits confidence in the completeness and balance of the synthesis.

↳ Enhancing Data Sharing Practices, paragraph 1

#positioning

Implementation trade-offs receive limited adjudication

Privacy, consent, security, regulator resources, and fragmentation are acknowledged, but their consequences for individual recommendations are not systematically traced. This leaves the feasibility and achievability claims less secure than the policy rationale.

↳ Participant-Level Data Sharing; Sharing of Clinical Study Reports; Future Directions; Conclusions

#application pathway

Recommendations lack adoption evidence

The paper offers no pilot, company-level implementation case, outcome evaluation, or sequencing plan for the proposed package. Its translation pathway therefore remains at the policy-framework stage.

↳ Table 1; Future Directions; Conclusions

Does this match your read? Add your assessment ↓

Nabu Commentary

Table 1 provides the article's main value by translating the 2013 commitments into detailed proposals covering eligibility, timing, review structures, documentation, and public disclosure. The surrounding sections are clearly organised and cite a broad policy landscape, while consistently distinguishing recommendations from established empirical findings. The principal constraint is methodological: the article offers no transparent account of how its decade of literature and policy sources was identified, selected, or appraised. Privacy, resource, consent, and infrastructure concerns are acknowledged, but the absence of implementation testing and detailed trade-off analysis limits confidence that the full package is immediately deployable.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
3.3±0.2

Contribution
3.5

The contribution is a concrete, itemised update to the 2013 commitments, including eligibility rules, disclosure timelines, independent review, and document-linking expectations. It meaningfully operationalises existing norms but primarily consolidates developments already advanced by regulators, journals, and funders.

Enhancing Data Sharing Practices, Table 1

The proposed updates provide clear recommendations regarding which data should be shared, when it should be shared, and under what conditions.

Methodological Rigour
3.1

The argument follows a consistent sequence from the 2013 principle through intervening developments to a proposed update, with empirical and policy claims generally cited. The article nevertheless gives no search strategy, source-selection criteria, or appraisal process for the decade of literature on which the synthesis rests.

Enhancing Data Sharing Practices, paragraphs 1–2

We have formulated these recommendations based on current literature and reported experiences.

Reporting
3.9

The six topic sections map directly onto Table 1, making the reasoning and recommendations easy to trace. Normative claims are generally marked with language such as “we propose” and “we recommend,” avoiding confusion with tested findings.

Table 1; Sharing of Protocols and Statistical Analysis Plans; Conclusions

Table 1 presents policy and process updates that are our perspectives—as based on the literature.

Positioning
3.3

The article situates its recommendations across FDA, EMA, Health Canada, WHO, NIH, ICMJE, EU CTR, FAIR, and other policy developments. It acknowledges privacy, consent, fragmentation, security, and resource constraints, but does not fully trace competing governance models and implementation burdens into its feasibility claims.

Progress and Challenges in Clinical Trial Data Sharing; Participant-Level Data Sharing; Future Directions

It is acknowledged that at present the data sharing landscape is fragmented in many aspects.

Reliability

No concerns4 of 4 checks


Internal CoherenceClean

The recommendations in Table 1 align with the accompanying sections, and empirical figures are presented as findings from cited investigations rather than original analyses. No internal contradiction or material language–evidence mismatch was identified.

Research ConductClean

The article reports no new human-participant research, statistical analysis, or original dataset requiring ethics approval, registration, or availability materials. Funding and conflict-of-interest declarations were not visible in the supplied text, but that absence does not establish a conduct concern for this perspective article.

Flags: 0 declared / 5 total

Reference IntegrityClean

44 of 44 checkable references verified

74 references in manuscript 30 have no canonical index record — counted, but not index-checkable citation details diverge from the cited records for 1 reference 3 references confirmed by manual review

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaPolicy and practice · SDG 3
Type of advanceSynthesis
Route to useNamed
AdvanceExtends
CitationsFWCI 6.7
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessFoundational
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The paper is a perspective offering recommendations grounded in literature review; no new intervention or mechanism is tested or shown working by the authors themselves.

From the paper
“this manuscript is expected to be particularly valuable for smaller pharmaceutical companies that have less established data sharing practices”

The paper names pharmaceutical companies as the actors who would adopt its recommended data sharing policy updates, though it does not specify the precise decision context beyond policy web pages and sharing processes.

Pathway

Pharmaceutical companies, PhRMA/EFPIA, and regulators would adopt the recommended updates to data sharing principles, changing industry policy and practice.

Barrier

Adoption depends on voluntary industry commitment, since no US or EU regulations mandate participant-level data sharing, and implementation requires resources and time.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. The Association of Physical Activity and Sedentary Behavior with Maternal and Cord Blood Anti-Oxidative Capacity and HDL Functionality: Findings of DALI Study

    Zafaranieh, Stadler, Pammer, et al. · 2023 · Health sciences

    Primary claim

    MVPA at <20 weeks and 24-28 weeks of gestation were positively associated with anti-oxidative capacity, as well as PON-1 activity of HDL in cord blood.

    Tentative
    Evidence Score
    2.7±0.2
    Reliability
    Caveats
  2. Physical activity and sedentary time across pregnancy and associations with neonatal weight, adiposity and cord blood parameters: a secondary analysis of the DALI study

    Dieberger, Obermayer-Pietsch, Harreiter, et al. · 2023 · Health sciences

    Primary claim

    Both higher maternal mean MVPA and increasing MVPA were associated with lower offspring FM% in males (-0.520%; 95% CI: -1.011%, -0.031% and -4.649%; -7.876%, -1.432% respectively).

    Tentative
    Evidence Score
    3.1±0.2
    Reliability
    Caveats
  3. Determinants of Changes in Women's and Men's Physical Activity and Sedentary Behavior across the Transition to Parenthood: A Focus Group Study

    Versele, Stok, Dieberger, et al. · 2022 · Health sciences

    Primary claim

    Four main levels of determinants [of changes in PA and SB across the transition to parenthood] were identified: the individual (including psychological, situational and biological determinants), interpersonal, environmental and policy level.

    Supported
    Evidence Score
    3.4±0.1
    Reliability
    No concerns

How the rubric works →